Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Tumor Associated Lymph Node T Cell
Advanced Solid Tumor
Immunotherapy

Interventions: Drug: Tumor Associated Lymph node T cell
Drug: cyclophosphamide
Drug: IL-2
Drug: Serplulimab Injection

First Posted Date: 2024-03-08

Last Posted Date: 2024-12-03

Lead Sponsor: Guangzhou FineImmune Biotechnology Co., LTD.

Target Recruit Count: 23

Registration Number: NCT06302062

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Gaungdong, China

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Epirubicin
Drug: Docetaxel
Drug: Carboplatin
Procedure: Breast Surgery
Drug: Capecitabine

First Posted Date: 2024-03-04

Last Posted Date: 2024-08-16

Lead Sponsor: University of Chicago

Target Recruit Count: 85

Registration Number: NCT06291064

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Phase 3

Recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Mosunetuzumab
Drug: Rituximab
Drug: Obinutuzumab
Drug: Bendamustin
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Doxorubicin
Drug: Vincristin
Drug: Prednisone

First Posted Date: 2024-02-28

Last Posted Date: 2024-10-11

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 790

Registration Number: NCT06284122

Locations: 🇫🇷
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France
🇫🇷
GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France
🇫🇷
CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France

and more 46 locations

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

Phase 1

Recruiting

Conditions: Lupus Nephritis - WHO Class III
Refractory Systemic Lupus Erythematosus
Lupus Nephritis - WHO Class IV

Interventions: Drug: AB-101
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab
Drug: Obinutuzumab

First Posted Date: 2024-02-20

Last Posted Date: 2024-07-12

Lead Sponsor: Artiva Biotherapeutics, Inc.

Target Recruit Count: 51

Registration Number: NCT06265220

Locations: 🇺🇸
University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
🇺🇸
University of California, San Diego, San Diego, California, United States

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory Mantle Cell Lymphoma

Interventions: Drug: KTE-X19
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-02-12

Last Posted Date: 2024-12-03

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 21

Registration Number: NCT06253663

Locations: 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
🇯🇵
Hokkaido University Hospital, Hokkaido, Japan
🇯🇵
Tohoku University Hospital, Miyagi, Japan

and more 5 locations

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer
Gastrointestinal Cancer
Ovarian Cancer
Metastatic Solid Cancers
Colorectal Cancer
Breast Cancer
Genitourinary Cancer

Interventions: Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: KRAS TCR-Transduced PBL
Biological: GRT-C903/GRT-R904

First Posted Date: 2024-02-12

Last Posted Date: 2025-01-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 210

Registration Number: NCT06253520

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: B-cell Non-Hodgkin Lymphoma

Interventions: Drug: Rocbrutinib
Biological: Rituximab
Drug: Cyclophosphamide
Drug: doxorubicin
Drug: Vincristin
Drug: Prednisone

First Posted Date: 2024-02-09

Last Posted Date: 2024-04-16

Lead Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.

Target Recruit Count: 112

Registration Number: NCT06251180

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Phase 1

Recruiting

Conditions: High Grade B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Doxorubicin
Procedure: Echocardiography
Drug: Etoposide
Procedure: Magnetic Resonance Imaging
Biological: Mosunetuzumab
Procedure: Multigated Acquisition Scan
Procedure: Positron Emission Tomography
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2024-02-08

Last Posted Date: 2024-07-23

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 40

Registration Number: NCT06249191

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Pembrolizumab
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Olaparib
Drug: Capecitabine

First Posted Date: 2024-02-07

Last Posted Date: 2024-05-08

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 30

Registration Number: NCT06245889

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: FT825
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine
Drug: Docetaxel
Drug: Cisplatin
Drug: Cetuximab

First Posted Date: 2024-02-05

Last Posted Date: 2024-12-24

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 351

Registration Number: NCT06241456

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy